The ARAMIS trial presented at the European Society of Cardiology Congress 2023 in Amsterdam evaluated the use of anakinra in acute myocarditis patients. Lead investigator Mathieu Kerneis highlighted the challenges of conducting trials in high-risk myocarditis patients due to their rarity. Anakinra, an interleukin-1 receptor antagonist, showed no significant benefit in reducing myocarditis complications in a low-risk population. The study emphasized the need for further research to explore anti-inflammatory strategies in higher-risk patients.
To Another Language
from source content
www.medscape.com
Key Insights Distilled From
by Sue Hughes at www.medscape.com 09-06-2023
https://www.medscape.com/viewarticle/996176Deeper Inquiries